1. Evaluation of New Thiazolide/Thiadiazolide Derivatives Reveals Nitro Group-Independent Efficacy against In Vitro Development of Cryptosporidium parvum▿
- Author
-
Jean-Jacques Ballet, Laetitia Le Goff, Jean-Francois Rossignol, Loïc Favennec, Gilles Gargala, and Andrew V. Stachulski
- Subjects
Stereochemistry ,Antiprotozoal Agents ,chemistry.chemical_compound ,Inhibitory Concentration 50 ,Structure-Activity Relationship ,Parasitic Sensitivity Tests ,medicine ,Moiety ,Structure–activity relationship ,Humans ,Pharmacology (medical) ,Experimental Therapeutics ,Thiazole ,IC50 ,Pharmacology ,Cryptosporidium parvum ,biology ,Thiadiazines ,Nitazoxanide ,biology.organism_classification ,Nitro Compounds ,In vitro ,Thiazoles ,Infectious Diseases ,chemistry ,Nitro ,medicine.drug - Abstract
Thirty-nine new thiazolide/thiadiazolide compounds were compared with the nitrothiazole nitazoxanide for activity against Cryptosporidium parvum development in HCT-8 cells. Twenty-seven agents exerted ≥90% inhibition. Agents with a lower 50% inhibitory concentration (IC 50 ) than nitazoxanide were either NO 2 or halogen 5 substituted on the thiazole moiety. Other 5 substitutions such as methyl, C 3 H 7 , C 6 H 11 , H, SO 2 CH 3 , and SCH 3 negatively impacted activity. Five-substituted deacetylated analogues exhibited higher IC 50 s than their acetylated counterparts. Halogeno-thiazolide/thiadiazolides may provide valuable nitro-free alternatives to nitazoxanide.
- Published
- 2010